![K M Seng](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
K M Seng
Plus aucun poste en cours
Profil
K M Seng is the founder of TauRx Therapeutics Ltd.
and TauRx Pharmaceuticals Ltd., both founded in 2002.
Anciens postes connus de K M Seng
Sociétés | Poste | Fin |
---|---|---|
TauRx Pharmaceuticals Ltd.
![]() TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Fondateur | - |
TauRx Therapeutics Ltd.
![]() TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Fondateur | - |
Expériences
Fonctions occupées
Sociétés liées
Entreprise privées | 2 |
---|---|
TauRx Therapeutics Ltd.
![]() TauRx Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology TauRx Therapeutics Ltd. develops treatments and diagnostics for a range of neurodegenerative diseases. It offers tau aggregation inhibitor, LMTX, a global Phase 3 clinical trials for Alzheimer’s and behavioural-variant Frontotemporal Dementia (bvFTD). LMTXT. The company was founded by Claude Wischik and K M Seng in 2002 and is headquartered in Singapore. | Health Technology |
TauRx Pharmaceuticals Ltd.
![]() TauRx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology TauRx Pharmaceuticals Ltd. developes drugs and diagnostics for neurodegenerative diseases. its pipeline includes LMTX, a tau aggregation inhibitor (TAI) for Alzheimer?s and Behavioural variant frontotemporal dementia diseases; anti-synuclein, a synuclein protein; early-stage compounds for use in therapies for neurodegenerative diseases; and diagnostic tests that assist clinicians in detecting and confirming the nature of a disease and monitoring the effects of therapy. The company was founded by Claude Wischik in 2002 and is headquartered in Singapore. | Health Technology |